Healthcare Sector Sees Biotech Boost as 2026 Budget Highlights Unveiled

The Union Budget 2026–27, presented by Finance Minister Nirmala Sitharaman, has placed a significant emphasis on strengthening India's healthcare and biopharma landscape. With a total allocation of ₹1,05,530 crore for the healthcare sector, this year's budget spotlights innovation, accessibility, and affordability in healthcare, marking key advancements in India's pursuit of becoming a global biopharma hub.

Biopharma SHAKTI: A ₹10,000-Crore Initiative

One of the standout announcements was the launch of the "Biopharma SHAKTI" initiative, which aims to transform India into a global leader in biopharmaceutical manufacturing. With a financial outlay of ₹10,000 crore over five years, this program targets the development and production of biologics and biosimilar drugs, which are crucial for addressing India's growing burden of non-communicable diseases (NCDs), including cancer, diabetes, and autoimmune disorders.

"This initiative - spanning manufacturing scale-up, global-grade regulation, new NIPER institutions, and a nationwide clinical trials network - can firmly position India as a global biopharma manufacturing hub", stated Kiran Mazumdar-Shaw, Chairperson of Biocon.

sbb-itb-8f61039

Custom Duty Exemptions on Lifesaving Drugs

To alleviate the treatment costs for patients, the government announced the exemption of basic customs duty on 17 cancer drugs and seven rare disease drugs. These include blockbuster therapies such as AbbVie’s venetoclax, Eli Lilly’s abemaciclib, and Novartis' Mekinist, which are critical for treating breast and blood cancers as well as other rare conditions.

Amitabh Dube, Country President and Managing Director of Novartis India, noted, "This signals the Government’s intent to improve access pathways for patients who depend on advanced treatments."

Building Capacity in Healthcare

The budget also places a strong emphasis on expanding India's healthcare workforce and infrastructure. Initiatives include the addition of 75,000 new medical seats, training 1.5 lakh caregivers, and upgrading allied health institutions over the next five years. This workforce expansion is aimed at addressing gaps in diagnostics, mental health, geriatric care, and rehabilitation services.

Gautam Khanna, CEO of P.D. Hinduja Hospital & Medical Research Centre, remarked, "The announcement to add 1 lakh Allied Healthcare Professionals over the next five years... is timely given India’s increasing elderly population."

Additionally, the government plans to establish 1,000 accredited clinical trial sites nationwide to strengthen India's capacity for high-quality, inclusive clinical research. These efforts align with the broader goal of positioning India as a trusted partner in global drug development.

Mental Health and Regional Medical Hubs

Mental health received a much-needed boost with the announcement of a second NIMHANS (National Institute of Mental Health and Neurosciences) and upgrades to mental health institutions in Ranchi and Tezpur. Furthermore, the budget proposes the creation of five regional healthcare hubs in partnership with the private sector, integrating advanced diagnostics, rehabilitation, AYUSH centers, and medical research facilities to promote medical tourism.

Dr. Devi Prasad Shetty, Founder and Chairman of Narayana Health, highlighted, "The proposal to develop regional medical hubs... addresses critical gaps in last-mile and mental healthcare."

Industry Leaders Respond

The Biopharma SHAKTI initiative and other healthcare reforms have received widespread praise from industry leaders. Dr. Prathap C. Reddy, Founder and Chairman of Apollo Hospitals, applauded the focus on allied health training and medical tourism hubs, stating, "Supporting states to create five hubs for medical tourism will elevate quality standards across regions."

Meenakshi Nevatia, Country President of Pfizer India, expressed confidence in scaling up manufacturing capabilities, saying, "These measures provide greater confidence to scale high-quality, globally compliant production in and from India."

A Step Toward Innovation-Driven Healthcare

With its focus on innovation, accessibility, and affordability, the Union Budget 2026–27 marks a decisive step toward enhancing India's healthcare ecosystem. Initiatives such as Biopharma SHAKTI, custom duty exemptions on lifesaving drugs, and workforce expansion signal a commitment to addressing both immediate patient needs and long-term national health goals. Leaders across the healthcare and pharma sectors have welcomed these measures as a transformative push toward making India a global leader in healthcare solutions.

As Satish Reddy, Chairman of Dr. Reddy’s Laboratories, aptly stated, "The ₹10,000-crore Biopharma Shakti programme will be a key enabler for India’s journey from volume to value leadership."

Read the source